Irbesartan Sandoz

Irbesartan, the active ingredient in Irbesartan Sandoz, is a selective Angiotensin II receptor blocker (ARB) presented as an oral tablet for oral administration. It is used to lower elevated blood pressure and to protect the kidneys in patients with diabetes, as well as to improve outcomes in heart failure.

GNH USA supplies Irbesartan Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to quality‑assured medicines for diverse healthcare settings and ensuring compliance with global regulatory standards.

Irbesartan acts on the renin‑angiotensin‑aldosterone system to control blood pressure and protect organ function.

Hypertension: reduces systolic and diastolic blood pressure, helping prevent cardiovascular events. Diabetic nephropathy: slows progression of kidney damage in patients with type 2 diabetes. Heart failure: improves symptoms and reduces hospitalizations in patients with chronic heart failure.

Irbesartan may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Dizziness - Headache - Fatigue - Nasal congestion - Diarrhea - Elevated serum potassium

Serious or Rare Side Effects: - Angioedema - Severe hypotension - Acute renal failure - Hepatic injury - Hyperkalemia - Neutropenia

When prescribing Irbesartan, clinicians should consider several safety measures to minimize risks.

Monitor blood pressure: check regularly to ensure therapeutic effect. Assess renal function: evaluate serum creatinine and eGFR before and during therapy. Check serum potassium: avoid hyperkalemia especially with concomitant potassium‑sparing agents. Use with caution in pregnancy: category D, avoid unless benefits outweigh risks. Avoid in severe hepatic impairment: dose adjustment may be required. Store at room temperature: keep in original packaging, protect from moisture and light.

Irbesartan can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Aliskiren (in diabetes) - ACE inhibitors (risk of angioedema and hyperkalemia) - Potassium‑sparing diuretics (risk of hyperkalemia) - Lithium (increased serum levels) - NSAIDs (reduced antihypertensive effect and renal risk)

Moderate Interactions (Monitor Closely): - Thiazide diuretics (potassium loss may require monitoring) - CYP2C9 inhibitors (e.g., fluconazole) (increase irbesartan levels) - CYP3A4 inhibitors (e.g., erythromycin) (moderate increase) - NSAIDs (monitor renal function) - Antidiabetic drugs (may need dose adjustment).